COVID-19 Clinical Trials in San Antonio

Showing 61-75 of 75 trials

Safety, Tolerability, and Pharmacokinetics of SAB-185 in Healthy Participants

NCT04468958

Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SAB Biotherapeutics has developed SAB-185, an Anti-SARS-CoV-2 Human Immunoglobulin Intravenous (transchromosomic \[Tc\] bovine-derived), as a potential therapeutic to treat COVID-19. This study will evaluate the safety, immunogenicity, and pharmacokinetics of SAB-185 in healthy participants.

COVID-19SARS-CoV2

SAb Biotherapeutics, Inc.28 participantsStarted Jul 2020

Wichita, Kansas, United States • Syracuse, New York, United States • San Antonio, Texas, United States

COMPLETED< 1 mile

COVID-19 Progression in End-Stage Kidney Disease

NCT04495907

The purpose of this study is to collect genomic and clinical data among a cohort of hemodialysis patients and analyze the association between genetic markers and the development and severity of illness in response to SARS-CoV-2.

SARS-CoV-2 Infection (Asymptomatic)SARS-CoV-2 Infection (Symptomatic)

Davita Clinical Research412 participantsStarted Aug 2020

Victorville, California, United States • Bridgeport, Connecticut, United States • Minneapolis, Minnesota, United States +8 more locations

Safety, Tolerability, and Pharmacokinetics of SAB-185 in Healthy Participants

COVID-19 Progression in End-Stage Kidney Disease

COVID-19 Trials in Other Cities

Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT)

NA-831, Atazanavir and Dexamethasone Combination Therapy for the Treatment of COVID-19 Infection

Tolerability and Efficacy of RJX in Patients With COVID-19

Study of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalized Patients

A Study of Opaganib in Coronavirus Disease 2019 Pneumonia

A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia

Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease

The Respiratory Protection Effectiveness Clinical Trial

A Study of Immune Responses to the Virus That Causes COVID-19

Investigation of the Efficacy of CARDIO Softgels PLUS Best-standard-of-care in the Recovery of Patients With COVID-19

Study to Evaluate a Single Dose of STI-2020 (COVI-AMG™) in Adults With Mild COVID-19 Symptoms

A Phase 3 Randomized Double Blind Efficacy and Safety Study of Oral Polio Vaccine and NA-831 for Covid-19

Clinical Evaluation of a Point-of-Care (POC), SARS-CoV-2 (COVID-19) IgG Antibody Test in Fingerstick Whole Blood

Other Conditions in San Antonio